Clarivate Plc

Clarivate Plc (CLVT) Market Cap

Clarivate Plc has a market capitalization of $1.54B.

Price: $2.41

-0.08 (-3.21%)

Market Cap: 1.54B

NYSE · time unavailable

CEO: Matitiahu Shem Tov

Sector: Technology

Industry: Information Technology Services

IPO Date: 2018-10-29

Website: https://www.clarivate.com

Clarivate Plc (CLVT) - Company Information

Market Cap: 1.54B|Sector: Technology

Company Profile

Clarivate Plc, an information services and analytics company, provides structured information and analytics for discovery, protection, and commercialization of scientific research, innovations, and brands. It offers Web of Science products and services, such as Web of Science, InCites, Journal Citation Reports, EndNote, ScholarOne, Converis, Publons, and Kopernio to organizations that plan, fund, implement, and utilize research; and Life Sciences products, including Cortellis and Newport Integrity for pharmaceutical and biotechnology companies to support research, market intelligence, and competitive monitoring in connection with the development and commercialization of new drugs. The company also provides Derwent products, which include Derwent Innovation, Techstreet, and IP Professional Services that enables its customers to evaluate the novelty of potential new products, confirm freedom to operate with respect to their product design, help them secure patent protection, assess the competitive technology landscape, and ensure that their products comply with required industry standards; CompuMark products, such as trademark screening, searching, and watching products and services for businesses and law firms; and MarkMonitor products, which helps enterprises to establish, manage, optimize, and protect their online presence. It serves government and academic institutions, life science companies, and research and development corporations in the Americas, the Middle East, Africa, Europe, and the Asia Pacific. The company was formerly known as Clarivate Analytics Plc and changed its name to Clarivate Plc in May 2020. Clarivate Plc is headquartered in London, the United Kingdom.

Analyst Sentiment

62%
Buy

From 9 Active Polls

1Y Forecast: $3.30

▲ +36.9% Potential Upside

Consensus Target Metrics

Low Bound

$3

Median

$3

High Bound

$4

Average

$3

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$3.30
▲ +36.93% Upside
Low Target
$3.00
24% Risk
Median Target
$3.30
37% Mid
High Target
$3.60
49% Max
Consensus
Hold
5 / 20 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,5411,6212,1852,5602,9302,7113,5705,1033,791
Enterprise Value ($M)5,6435,7236,3356,7217,1546,9527,8689,4278,146
Price to Earnings Ratio (P/E)-11.24-10.08176.21-22.61-10.17-6.52-4.65-19.45-3.11
Price/Earnings-to-Growth Ratio (PEG)-82.65-2.18-0.71-0.66
Price to Sales Ratio (P/S)0.632.773.544.114.714.575.388.205.83
Price to Book Ratio (P/B)0.320.340.450.520.590.540.690.930.68
Price to Free Cash Flow Ratio (P/FCF)2.5820.546.2022.1658.2424.5860.4140.4062.88
Enterprise Value to Sales (EV/Sales)9.7710.2710.7911.5111.7111.8715.1512.53
Enterprise Value to EBITDA (EV/EBITDA)6.4226.7227.4828.5036.1742.2463.6047.39-146.52
Debt to Equity Ratio4.670.910.920.910.920.910.890.850.84
⚠️

Valuation Model Suspended

API Payload Error: Inverted or negative baseline Free Cash Flow margin detected (-3.5%).

Troubleshooting Notice: The upstream financial data supplier has uploaded corrupted or inverted baseline metrics for CLVT. The server sandbox cannot calculate an intrinsic value path from negative cash generation baselines.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 CLARIVATE PLC (CLVT) — Investment Overview

🧩 Business Model Overview

Clarivate provides research and intellectual-property (“IP”) intelligence through subscription databases and workflow tools. In research workflows, Clarivate’s products support scholarly discovery, citation analytics, grant and portfolio decisions, and research evaluation. In IP workflows, Clarivate products support patent search, patent landscape analytics, and competitive monitoring across prosecution strategy and enforcement planning. The value proposition centers on curated, structured data and analytics embedded into recurring decision processes for universities, government bodies, and corporate R&D/IP organizations.

💰 Revenue Streams & Monetisation Model

The revenue model is primarily subscription-led: institutional and enterprise customers pay for access to databases, analytics platforms, and related software-enabled services. Monetisation typically reflects:

  • Recurring subscriptions tied to usage and seat/device structures, supporting high renewal visibility.
  • Tiered analytics and workflow add-ons that expand within the same account over time as customers adopt more modules (e.g., deeper citation analytics, research performance measurement, or IP landscape capabilities).
  • Professional and service components that supplement subscriptions (implementation, training, and specialized analytics), usually with a smaller contribution than recurring access fees.

Margin structure generally benefits from a software/data cost base: once content, taxonomy, and platform infrastructure are built and maintained, incremental revenue tends to scale with less proportional cost, while customer retention and expansion drive operating leverage.

🧠 Competitive Advantages & Market Positioning

Clarivate’s core moat is a combination of high switching costs and intangible assets (proprietary data curation, classification systems, and analytic frameworks).

  • Switching Costs (Workflow + Data Gravity): Customers integrate Clarivate outputs into internal reporting, research evaluation, and IP strategy processes. Historical baselines, standardized fields, and user training create inertia, making replacement across platforms costly and operationally disruptive.
  • Intangible Assets (Curated Data + Analytics): Maintaining reliable coverage, cleaning, normalization, and evolving classification logic is difficult. Competitors can assemble data from sources, but replicating Clarivate’s structured, validated, and analytics-ready datasets is a sustained investment effort.
  • Embedded Enterprise Relationships: Institutional procurement cycles and multi-year licensing arrangements reinforce retention, particularly where evaluation frameworks and compliance requirements rely on consistent data methodologies.

Competitive benchmarking:

  • Elsevier (RELX) — strong in scholarly indexing and research analytics, with a broad footprint in academic publishing. Clarivate’s emphasis spans both scholarly intelligence and IP analytics within a unified enterprise workflow for discovery and competitive positioning.
  • Springer Nature / Dimensions — a research analytics alternative. Clarivate differentiates through the depth of curated data workflows and a comparatively larger focus on linking research evaluation needs with IP-oriented intelligence.
  • Questel (and peers such as CPA Global) — focused heavily on IP/patent intelligence. Clarivate’s competitive positioning leverages cross-domain datasets and analytics to serve both corporate R&D decision-making and IP strategy, where buyers often seek an integrated intelligence layer rather than point solutions.

🚀 Multi-Year Growth Drivers

Over a 5–10 year horizon, Clarivate’s addressable market expands through structural demand for data-driven decision support in R&D and IP.

  • Increasing R&D complexity and volume: More publications, more collaborations, and more multidisciplinary work elevate the value of robust discovery, normalization, and evaluation analytics.
  • Growing importance of patent landscape and competitive intelligence: Higher global IP activity increases demand for faster, more accurate searching and landscape modeling.
  • Institutional accountability and research evaluation: Governments, universities, and research funders increasingly require auditable, consistent metrics for portfolio decisions—benefiting providers with stable methodologies.
  • Workflow digitization and integration: Customers adopt tools that embed intelligence into end-to-end processes (search → evaluation → strategy), supporting upsell opportunities from foundational access into advanced analytics modules.
  • AI-assisted research and IP analysis: AI does not remove the need for curated, structured inputs. Organizations still require authoritative datasets, normalization, and consistent taxonomies to use AI outputs responsibly—supporting ongoing demand for high-quality data infrastructure.

⚠ Risk Factors to Monitor

  • Pricing pressure and competitive displacement: Public and private competitors may discount or bundle content/services, challenging renewal rates and expansion economics.
  • Data integrity and platform performance: Any degradation in data quality, classification accuracy, coverage, or analytics reliability can increase churn and reduce customer trust.
  • Technological disruption in scholarly and IP discovery: New search paradigms or data access models could reduce perceived differentiation if customers believe they can substitute analytics with alternative tools.
  • Customer concentration and budget cyclicality: Public-sector and academic budgets can influence renewal timing and module adoption.
  • Acquisition integration risk: Product portfolio integration, retention of key customers, and realization of synergy targets can affect the medium-term margin profile.
  • Regulatory and privacy/sublicensing constraints: Licensing terms for content and compliance requirements tied to data handling can impact operating flexibility.

📊 Valuation & Market View

The market typically values data/software and subscription information providers using a mix of EV/EBITDA and P/S, with equity sensitivity to subscription quality. Valuation tends to move with:

  • Recurring revenue durability (renewal rates, churn control).
  • Operating margin stability and operating leverage (software/data cost discipline and disciplined spending).
  • Expansion within installed accounts (module adoption and usage-driven upsells).
  • Free cash flow conversion (maintenance of predictable working capital needs and capex intensity).

Given the subscription-led profile and retention-driven economics, investors generally reward businesses that demonstrate consistent renewal strength and incremental monetisation across their customer base.

🔍 Investment Takeaway

Clarivate’s long-term thesis rests on structural switching costs and durable intangible assets in curated research and IP intelligence. The company competes in a market with credible, well-funded rivals, yet Clarivate’s embedded workflows and proprietary data/analytics frameworks make replacement operationally difficult for institutional and enterprise customers. Upside appears tied to sustained subscription renewals and continued account expansion as R&D and patent strategy demand grows, while key risks center on competitive pricing pressure and maintaining data/analytics reliability.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for CLVT.

gurufocus.com2026-05-29

Clarivate Introduces IPOne

Clarivate Introduces IPOne PR Newswire LONDON, May 29, 2026 A unified IP intelligen

prnewswire.com2026-05-29

Clarivate Introduces IPOne

A unified IP intelligence platform for AI-powered research ecosystem, workflow automation and enterprise AI connectors LONDON, May 29, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced IPOne, a unified platform that combines purpose-built AI agents and trusted proprietary data to power intellectual property (IP) research and workflows across enterprise environments. IPOne is being developed in collaboration with leading corporate IP teams and law firms to support real-world IP workflows.

prnewswire.com2026-05-21

Clarivate's IPfolio and Renewal Services Selected by IGT

Managing global intellectual property more efficiently with trusted data, expert support and integrated services LONDON, May 21, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced that IPfolio has been selected by IGT, a global leader in gaming, as its IP management platform, along with Clarivate patent annuity and trademark renewal services, to support the management of its global intellectual property (IP) portfolio. IPfolio provides IGT with a modern, scalable platform for IP management, bringing together trusted data, deep domain expertise and integrated services in a single platform.

gurufocus.com2026-05-19

Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform PR Newswire

prnewswire.com2026-05-19

Clarivate Selected By Czech National Library of Technology to Develop Unified National Library Platform

New cloud-based, shared platform based on Alma and Primo to help National Library of Technology advance library services and information accessibility LONDON, May 19, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, announced today that the Czech National Library of Technology has selected Clarivate to deliver its new unified library services and discovery platform as part of a ten-year agreement. The cloud-based library solution will help the National Library of Technology advance the modernization of academic and research libraries in the Czech Republic while supporting the Library's vision for national-scale discovery and resource management.

seekingalpha.com2026-05-13

Clarivate: Business Showed Signs Of Stabilization, But It Is Not Enough

Clarivate delivered improved Q1 2026 results, with organic growth turning positive at 0.6% and margin expansion, but reported revenue still declined year over year. Segment trends stabilized, notably with Academia & Government and Life Sciences & Healthcare returning to growth, though IPPG remained a drag at -1.3% organic growth. AI-driven product enhancements and the Value Creation Plan could accelerate organic growth, but sustained improvement is needed before a re-rating is justified.

prnewswire.com2026-05-06

Clarivate launches Web of Science Research Intelligence

AI-native research intelligence platform for research funding, strategy and impact now available globally to institutions LONDON, May 6, 2026 /PRNewswire/ -- Clarivate Plc (NYSE:CLVT), a leading global provider of transformative intelligence, today announced the global launch of Web of Science Research Intelligence, an AI-native research intelligence platform designed to support decision-making across funding, strategy and impact for research institutions. Developed in close partnership with the global research community and shaped by more than 50 development partners and early adopters across 20 countries, Web of Science Research Intelligence is now available to institutions worldwide.

fool.com2026-05-01

Why Clarivate Stock Was Soaring This Week

The company significantly widened its net margin in the first quarter, and the market noticed.

seekingalpha.com2026-04-29

Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

Clarivate Plc (CLVT) Q1 2026 Earnings Call Transcript

zacks.com2026-04-29

Compared to Estimates, Clarivate (CLVT) Q1 Earnings: A Look at Key Metrics

Although the revenue and EPS for Clarivate (CLVT) give a sense of how its business performed in the quarter ended March 2026, it might be worth considering how some key metrics compare with Wall Street estimates and the year-ago numbers.

zacks.com2026-04-29

Clarivate PLC (CLVT) Tops Q1 Earnings and Revenue Estimates

Clarivate PLC (CLVT) came out with quarterly earnings of $0.18 per share, beating the Zacks Consensus Estimate of $0.14 per share. This compares to earnings of $0.14 per share a year ago.

prnewswire.com2026-04-29

Clarivate Reports First Quarter 2026 Results

— Value Creation Plan delivering accelerated organic revenue growth — — Utilized solid free cash flow generation to deleverage — — Reaffirms 2026 financial outlook — LONDON, April 29, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT) (the "Company" or "Clarivate"), a leading global provider of transformative intelligence, today reported results for the first quarter ended March 31, 2026. Executive Commentary Matti Shem Tov, Chief Executive Officer: "We are off to a solid start to 2026, with first‑quarter results demonstrating tangible progress against the Value Creation Plan we launched in early 2025.

prnewswire.com2026-04-28

Clarivate Introduces Nexus Connect, the First Institutional AI Gateway to Trusted Research and Learning

Nexus Connect provides a single, university-branded connector inside AI chat agents, giving students and researchers seamless access to scholarly resources and services. LONDON, April 28, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced Nexus Connect, an AI gateway to universities' academic resources and services.

prnewswire.com2026-04-15

Clarivate to Report First Quarter 2026 Results on April 29, 2026

LONDON, April 15, 2026 /PRNewswire/ -- Clarivate Plc (NYSE: CLVT), a leading global provider of transformative intelligence, today announced it will report its financial results for the first quarter 2026 before the market opens on Wednesday, April 29, 2026. The press release and earnings supplement, with accompanying financial information, will be available on the Clarivate investor website at https://ir.clarivate.com.

defenseworld.net2026-04-01

Analyzing 3 E Network Technology Group (NASDAQ:MASK) and Clarivate (NYSE:CLVT)

Clarivate (NYSE: CLVT - Get Free Report) and 3 E Network Technology Group (NASDAQ: MASK - Get Free Report) are both small-cap computer and technology companies, but which is the superior stock? We will contrast the two companies based on the strength of their valuation, profitability, risk, earnings, institutional ownership, analyst recommendations and dividends. Valuation and Earnings

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"CLVT reported Q1’26 revenue of $585.5M and EPS of -$0.0627. Net loss was -$40.2M (net margin -6.9%). YoY, revenue rose 1.5% (from $593.7M in Q1’25) while net income deteriorated sharply from -$103.9M to -$40.2M (an improvement of ~$63.7M; still negative). QoQ, revenue declined 5.2% (from $617.0M in Q4’25) and net income swung from +$3.1M to -$40.2M. Profitability was volatile: gross margin improved slightly vs Q1’25 (65.1% vs 65.1% broadly flat) but operating margin contracted sequentially (5.2% in Q1’26 vs 6.7% in Q4’25). Despite the weaker bottom line, operating cash flow remained strong at $134.7M and free cash flow was $78.9M, supporting liquidity even with a cash balance declining to $242.2M from $329.2M. Balance sheet resilience is mixed for a non-bank: total assets were $10.93B (down vs $11.07B in Q4’25), equity was $4.79B (slightly down), and net debt remained very high at ~$4.09B, indicating continued leverage pressure. Shareholder returns appear negative—price is $2.68 and the 1y change is -22.99%, with no dividend or buybacks reflected in cash flow. Analyst valuation context shows a consensus target of ~$3.3 versus the current ~$2.68 (upside implied), but recent earnings volatility likely tempers near-term sentiment."

Revenue Growth

Fair

Revenue was $585.5M in Q1’26: +1.5% YoY (vs $593.7M in Q1’25) but -5.2% QoQ (vs $617.0M in Q4’25). Trajectory looks soft sequentially.

Profitability

Neutral

Net income improved YoY (loss narrowed from -$103.9M to -$40.2M), but QoQ profitability deteriorated (Q4’25 net income +$3.1M to Q1’26 -$40.2M). Operating margin fell sequentially (5.2% vs 6.7%).

Cash Flow Quality

Neutral

Operating cash flow was strong at $134.7M and free cash flow was $78.9M in Q1’26 despite a net loss. No dividends were paid; buybacks were not reported in Q1’26 cash flow.

Leverage & Balance Sheet

Neutral

Leverage remains heavy: net debt ~$4.09B and total debt ~$4.33B. Equity was slightly lower QoQ ($4.79B vs $4.84B), suggesting limited balance-sheet buffer.

Shareholder Returns

Neutral

Total shareholder value likely negative: stock price at $2.68 with -22.99% 1y_change. No dividend yield (0%) and no clear Q1 buyback support in the provided cash flow.

Analyst Sentiment & Valuation

Fair

Consensus target ~$3.3 implies upside vs current ~$2.68, but earnings volatility (net loss after a profitable quarter) likely constrains multiple expansion.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

Clarivate’s Q1 2026 showed improving underlying fundamentals driven by subscription mix, renewal discipline, and AI-enabled efficiency. Revenue was $586M and adjusted diluted EPS rose to $0.18 (~+$0.04 YoY). The key operational signal was adjusted EBITDA of $241M with a 41% margin, up almost 200 bps YoY, and renewal rates improving ~100 bps—supporting organic ACV moving to nearly flat. Free cash flow was ~$79M, but down YoY due to working-capital/incentive compensation timing, while management simultaneously reduced debt ($143M total; including $100M bond redemption and $43M bond repurchases). Guidance was reaffirmed: organic ACV +2% to +3% (midpoint), adjusted EBITDA margin expanding ~200 bps to ~43%, and free cash flow to ~$400M at midpoint. Main uncertainties are transactional weakness (ANG timing; Life Sciences subscription migration) and LS&H sale optionality, which could change future guidance.

AI IconGrowth Catalysts

  • Subscription-first progress: organic ACV +1.6% and subscription organic revenue +1.7% in Q1
  • Institutional win: multiproduct institutional deal with Fuyao University (China) expanding China footprint
  • AI-driven customer efficiency in Academic: 30%-60% decrease in manual repetitive work; 2x to 4x throughput
  • IP renewal discipline: renewal rates improved ~100 bps in Q1, driving organic ACV nearly flat
  • Life Sciences: new top-20 global pharma customer for DRG Fusion; additional 6-figure OpEx subscription wins

Business Development

  • Multiproduct institutional deal with Fuyao University (China) in Academic & Government
  • Trademark analytics + large-scale digitization programs with national IP offices, including the U.S. PTO
  • Integrated Cortellis regulatory intelligence with Anthropic Cloud Enterprise (AI workflow embedding)
  • Collaboration with Anthropic to enable CRI proprietary data consumption within Anthropic Enterprise Customers
  • Nexus Connect (Academic & Government): brings Clarivate data into ChatGPT/Copilot-style LLM workflows

AI IconFinancial Highlights

  • Revenue: $586M; Q1 adjusted diluted EPS $0.18, up nearly 30% (~+$0.04 YoY)
  • Adjusted EBITDA: $241M; margin 41%, up almost 200 bps YoY (discipline + subscription-first mix)
  • Free cash flow: ~$79M in Q1 (OP C F $135M), with $31M decrease YoY driven by higher working capital from incentive compensation
  • Renewal rates improved ~100 bps; organic ACV trending improved to nearly flat
  • FX tailwind: weaker USD vs prior year basket contributed top-line benefit
  • Net loss: $40M; $64M improvement YoY driven by FX benefit plus lower restructuring, income tax, and interest expenses
  • Mid-teens profit conversion impact referenced: transaction gains last year did not recur this year

AI IconCapital Funding

  • Debt reduction: retired $143M of debt during the quarter
  • Redeemed remaining $100M of bonds due later in the year
  • Repurchased $43M of bonds due 2028 and 2029 at ~10% blended discount
  • Repurchased 7M shares to offset dilutive impact of stock compensation
  • Guidance-level capital strategy: use remaining 2026 free cash flow for debt reduction

AI IconStrategy & Ops

  • Value creation plan pillars driving results: business model optimization, improved sales execution, accelerated AI innovation, and portfolio rationalization
  • AI deployment internally: digital agents expected to reduce manual effort, improve accuracy, and create operating leverage (sales/customer care, technology/content ops, and corporate automation)
  • Go-to-market automation/efficiency: AI embedded in sales and customer care; AI in software engineering/content operations to shorten new product time to market
  • Portfolio rationalization: actively pursuing the sale of the Life Sciences & Health business (LS&H); process ongoing with no guaranteed outcome

AI IconMarket Outlook

  • Full-year organic annual contract value (ACV) growth: +2% to +3% (midpoint +0.75 percentage point)
  • Full-year recurring organic growth: ~1.5% at midpoint (nearly +1 pp vs last year)
  • Full-year revenue decline: about -$100M at midpoint due to disposals to LS&H (total revenue guidance to $2.36B at midpoint)
  • Organic recurring revenue mix ex-disposals: 88% to 90%
  • Adjusted EBITDA margin: expansion ~200 bps at midpoint to nearly 43%
  • Adjusted diluted EPS: +~9% at midpoint to $0.75 (share repurchases from prior year cited)
  • Free cash flow: +~10% to ~$400M at midpoint
  • Foreign exchange translation benefit: ~$10M top-line and ~$5M bottom-line (most already seen in Q1)
  • Seasonality: slight sequential pullback in Q1 annual contract value organic growth; expects steady acceleration through year with slight Q2 patent-renewal phasing effects and Q4 tick-up from normal recurring/transactional seasonality
  • Deleveraging plan: retire secured notes entirely before July 2028 (over next 9 quarters); then retire 2029 notes, leaving ~$0.5B of $1.8B mid-term maturities to refinance
  • Net leverage target: from 4.0 turns at end of Q1 2026 to ~2.5 turns in a few years

AI IconRisks & Headwinds

  • Intellectual Property volatility: early-year environment described as muted; patent renewal comps/timing expected to make first half slightly down; expects return to growth in second half
  • Transactional revenue down: Q1 transactional revenues down a couple percent; ANG affected by software implementation timing and Life Sciences subscription migration headwind
  • LS&H divestiture uncertainty: guidance assumes LS&H owned for full year; if sale agreed, guidance may be revised
  • Working capital variability: free cash flow down YoY due to incentive compensation payments (higher working capital use)

Q&A: Analyst Interest

  • AI traction and efficiency quantification: Management described AI in three product waves (assistants, agents, ecosystem embedding), cited measured customer impact (2x-4x throughput and 30%-60% less manual work), and stated they are also using AI for internal margin expansion and operational leverage.
  • Competitive environment comparison: Management said they do not anchor on competitors but emphasized external recognition as an AI innovator and described adoption metrics across Academic & Government (more than institutional users; Nexus Connect) and Life Science and IT (10,000+ researchers/users), plus Anthropic collaboration.
  • IP segment turnaround timing and renewals: Management referenced improved IP renewal rates (~100 bps in Q1) and organic ACV “pretty close to flat” after years of decline; they expect patent renewal recurring revenue to be slightly down in H1 due to comps, then return to growth in H2.

Sentiment: MIXED

Note: This summary was synthesized by AI from the CLVT Q1 2026 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for CLVT.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (CLVT)

© 2026 Stock Market Info — Clarivate Plc (CLVT) Financial Profile